Basel Medical Group Ltd (NASDAQ:BMGL) price on Thursday, July 03, fall -1.15% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.72.
A look at the stock’s price movement, the close in the last trading session was $1.74, moving within a range at $1.6001 and $1.765. The PE ratio in trailing twelve months stood at 80.75. Turning to its 52-week performance, $9.40 and $0.91 were the 52-week high and 52-week low respectively. Overall, BMGL moved -66.21% over the past month.
Basel Medical Group Ltd’s market cap currently stands at around $32.32 million, with investors looking forward to this quarter’s earnings report slated for in August.
BMGL’s current price about -39.34% and -46.77% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 39.04, while 7-day volatility ratio is 13.73% and 20.39% in the 30-day chart. Further, Basel Medical Group Ltd (BMGL) has a beta value of 0.
If we refocus on Basel Medical Group Ltd (NASDAQ:BMGL), historical trading data shows that trading volumes averaged 0.59 over the past 10 days and 5.62 million over the past 3 months. The company’s latest data on shares outstanding shows there are 18.75 million shares.
The 69.02% of Basel Medical Group Ltd’s shares are in the hands of company insiders. Also important is the data on short interest which shows that short shares stood at 0.44 million on 2025-06-13, giving us a short ratio of 0.03. The data shows that as of 2025-06-13 short interest in Basel Medical Group Ltd (BMGL) stood at 509.0 of shares outstanding, with shares short rising to 0.29 million registered in 2025-05-15. It is this reason that could see investor optimism for the BMGL stock continues to rise going into the next quarter.
